Asthma improvement in patients treated with dupilumab for severe atopic dermatitis
IntroductionAtopic dermatitis (AD) is considered a systemic type 2 immune driven disease, and it is associated to many atopic comorbidities including asthma. The aim of our study was to prospectively evaluate the respiratory outcomes in patients with persistent allergic asthma treated with dupilumab...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-09-01
|
| Series: | Frontiers in Allergy |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/falgy.2023.1223657/full |
| _version_ | 1827820842402185216 |
|---|---|
| author | Marco Dubini Valentina Benzecry Federica Rivolta Andrea Sangalli Angelo Valerio Marzano Angelo Valerio Marzano Valerio Pravettoni Simona Tavecchio Silvia Mariel Ferrucci |
| author_facet | Marco Dubini Valentina Benzecry Federica Rivolta Andrea Sangalli Angelo Valerio Marzano Angelo Valerio Marzano Valerio Pravettoni Simona Tavecchio Silvia Mariel Ferrucci |
| author_sort | Marco Dubini |
| collection | DOAJ |
| description | IntroductionAtopic dermatitis (AD) is considered a systemic type 2 immune driven disease, and it is associated to many atopic comorbidities including asthma. The aim of our study was to prospectively evaluate the respiratory outcomes in patients with persistent allergic asthma treated with dupilumab due to severe AD (sAD).MethodsWe enrolled eligible patients with sAD for dupilumab treatment from September 2018 to December 2020. We then selected the subgroup of patients sensitized to perennial allergens. Dupilumab's efficacy and safety on AD and comorbid asthma were assessed at baseline, one month, four months, and then every 4 months up to one year.ResultsA total of 437 patients with sAD were enrolled for dupilumab treatment due to sAD, and 273 reached 48 weeks of therapy. Respiratory outcomes were evaluated in the 85 asthmatic patients with positivity only to perennial allergens. Our patients showed statistically and clinically significant improvement in asthma control (Asthma Control Test and Asthma Control Questionnaire) and airway obstruction parameters (FEV1), in addition to the expected AD-related skin outcomes. Specifically, a significant improvement was achieved at the fourth month of dupilumab therapy, and this trend was maintained up to twelve months, regardless of asthma severity.ConclusionsOur results showed the overall improvement of the clinical picture that dupilumab offers for patients with severe AD and persistent allergic asthma of any severity, highlighting the importance of a global multidisciplinary approach of type 2 driven disease. |
| first_indexed | 2024-03-12T01:33:48Z |
| format | Article |
| id | doaj.art-0287e73876a24c7c84d85e726dfcb8a8 |
| institution | Directory Open Access Journal |
| issn | 2673-6101 |
| language | English |
| last_indexed | 2024-03-12T01:33:48Z |
| publishDate | 2023-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Allergy |
| spelling | doaj.art-0287e73876a24c7c84d85e726dfcb8a82023-09-11T09:29:58ZengFrontiers Media S.A.Frontiers in Allergy2673-61012023-09-01410.3389/falgy.2023.12236571223657Asthma improvement in patients treated with dupilumab for severe atopic dermatitisMarco Dubini0Valentina Benzecry1Federica Rivolta2Andrea Sangalli3Angelo Valerio Marzano4Angelo Valerio Marzano5Valerio Pravettoni6Simona Tavecchio7Silvia Mariel Ferrucci8Department of Internal Medicine, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDepartment of Internal Medicine, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDepartment of Internal Medicine, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDepartment of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, ItalyDepartment of Internal Medicine, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDepartment of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, ItalyDermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyIntroductionAtopic dermatitis (AD) is considered a systemic type 2 immune driven disease, and it is associated to many atopic comorbidities including asthma. The aim of our study was to prospectively evaluate the respiratory outcomes in patients with persistent allergic asthma treated with dupilumab due to severe AD (sAD).MethodsWe enrolled eligible patients with sAD for dupilumab treatment from September 2018 to December 2020. We then selected the subgroup of patients sensitized to perennial allergens. Dupilumab's efficacy and safety on AD and comorbid asthma were assessed at baseline, one month, four months, and then every 4 months up to one year.ResultsA total of 437 patients with sAD were enrolled for dupilumab treatment due to sAD, and 273 reached 48 weeks of therapy. Respiratory outcomes were evaluated in the 85 asthmatic patients with positivity only to perennial allergens. Our patients showed statistically and clinically significant improvement in asthma control (Asthma Control Test and Asthma Control Questionnaire) and airway obstruction parameters (FEV1), in addition to the expected AD-related skin outcomes. Specifically, a significant improvement was achieved at the fourth month of dupilumab therapy, and this trend was maintained up to twelve months, regardless of asthma severity.ConclusionsOur results showed the overall improvement of the clinical picture that dupilumab offers for patients with severe AD and persistent allergic asthma of any severity, highlighting the importance of a global multidisciplinary approach of type 2 driven disease.https://www.frontiersin.org/articles/10.3389/falgy.2023.1223657/fulldupilumabasthmaatopic dermatitisatopic comorbiditiestype 2 diseaseallergic asthma |
| spellingShingle | Marco Dubini Valentina Benzecry Federica Rivolta Andrea Sangalli Angelo Valerio Marzano Angelo Valerio Marzano Valerio Pravettoni Simona Tavecchio Silvia Mariel Ferrucci Asthma improvement in patients treated with dupilumab for severe atopic dermatitis Frontiers in Allergy dupilumab asthma atopic dermatitis atopic comorbidities type 2 disease allergic asthma |
| title | Asthma improvement in patients treated with dupilumab for severe atopic dermatitis |
| title_full | Asthma improvement in patients treated with dupilumab for severe atopic dermatitis |
| title_fullStr | Asthma improvement in patients treated with dupilumab for severe atopic dermatitis |
| title_full_unstemmed | Asthma improvement in patients treated with dupilumab for severe atopic dermatitis |
| title_short | Asthma improvement in patients treated with dupilumab for severe atopic dermatitis |
| title_sort | asthma improvement in patients treated with dupilumab for severe atopic dermatitis |
| topic | dupilumab asthma atopic dermatitis atopic comorbidities type 2 disease allergic asthma |
| url | https://www.frontiersin.org/articles/10.3389/falgy.2023.1223657/full |
| work_keys_str_mv | AT marcodubini asthmaimprovementinpatientstreatedwithdupilumabforsevereatopicdermatitis AT valentinabenzecry asthmaimprovementinpatientstreatedwithdupilumabforsevereatopicdermatitis AT federicarivolta asthmaimprovementinpatientstreatedwithdupilumabforsevereatopicdermatitis AT andreasangalli asthmaimprovementinpatientstreatedwithdupilumabforsevereatopicdermatitis AT angelovaleriomarzano asthmaimprovementinpatientstreatedwithdupilumabforsevereatopicdermatitis AT angelovaleriomarzano asthmaimprovementinpatientstreatedwithdupilumabforsevereatopicdermatitis AT valeriopravettoni asthmaimprovementinpatientstreatedwithdupilumabforsevereatopicdermatitis AT simonatavecchio asthmaimprovementinpatientstreatedwithdupilumabforsevereatopicdermatitis AT silviamarielferrucci asthmaimprovementinpatientstreatedwithdupilumabforsevereatopicdermatitis |